Effects and Safety of Metronidazole in Patients With Gastrectomy
Information source: The Catholic University of Korea
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post Gastrectomy State
Intervention: metronidazole (Drug); Placebo (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: The Catholic University of Korea
Summary
Recent study showed that SIBO is common among postgastrectomy patients and It appears to be
associated with postprandial intestinal symptoms and might aggravate late hypoglycemia. SIBO
could be a new therapeutic target for managing intestinal symptoms in postgastrectomy
patients. The purpose of this study is to determine whether antiboitic (metronidazole) is
effective in patients with postgasrectomy syndrome
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Patient's Global Assessment of abdominal symptom
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age between 18 and 70
- gastrectomy for early gastric cancer with complete resection
- no reccurrence after follow up more than 6 months
- identified small bowel bacterial overgrowth by hydrogen breath test
- symptoms of postgastrectomy syndrome
Exclusion Criteria:
- hypersensive to metronidazole
- systemic chemotherapy history
- other organic gastrointestinal disease (inflammatory bowel disease, carcinoid
syndrome, amyloidosis, intestinal obstruction)
- other gastrointestinal operation history except appendectomy, cholecystectomy)
- recent colonoscopic examination (within 30 days)
- uncontrolled psychopathy
- drug or alcohol abuser
- pregnant or breast feeding woman
- recent history of antibiotics treatment (within 90 days)
- recent history of PPI or H2 blocker treatment (within 30 dyas)
- recent history of probiotics treatment (within 30 dyas)
- recent history of prokinetics or antispasmotic treatment (within 15 days)
- severe systemic illness
Locations and Contacts
Additional Information
Starting date: May 2011
Last updated: August 6, 2012
|